Athletic PerformanceTCP600-RESPNCT07710547
TCP-600 Supplementation and Performance Response in Professional Football Players
A study testing Taurine, Caffeine and Phosphatidylserine in people with Athletic Performance and Cognitive Fatigue, run by Vizja University in Warsaw at 3 sites in Poland.
Trial summary
This 28-day randomised, placebo- and active-controlled trial investigated multidimensional responses to taurine-caffeine supplementation with or without phosphatidylserine in 65 male professional and highly trained football players. Read more about this study
- Who is it for?
- Ages 18 to 37 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Athletic Performance, Cognitive Fatigue, Exercise Recovery
- What is being tested?
- Taurine, Caffeine and Phosphatidylserine
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 65 participants
- Where
- 3 sitesPoland
- Study dates
- 7 Sep 2026to 8 Oct 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 37 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Male professional or highly trained football players aged 18-37 years.
- Regular participation in structured football training and team activities.
- Minimum of 5 years of structured football training experience.
- Regular involvement in club training during the study period.
- Medical clearance or no known contraindications to high-intensity exercise testing.
- Ability to complete sprint, reaction-time, cognitive-fatigue, heart-rate-variability, wellness/readiness, and selected football-specific perceptual-cognitive assessments where available.
Show all 10Show fewer
- Willingness to maintain usual diet and training habits during the study period.
- Willingness to avoid additional ergogenic supplements outside the study protocol during the intervention.
- Willingness to follow caffeine restrictions before testing sessions.
- Written informed consent provided before participation.
Who cannot join
- Current musculoskeletal injury or illness preventing full participation in training or testing.
- Musculoskeletal injury within the previous 3 months that may affect sprint, football-specific performance, or perceptual-cognitive testing.
- Cardiovascular, metabolic, neurological, psychiatric, or other chronic disease that may affect safety or study outcomes.
- Diagnosed sleep disorder.
- Use of medication affecting heart rate, autonomic nervous system function, sleep, cognition, or exercise performance.
- Known hypersensitivity or intolerance to caffeine, taurine, phosphatidylserine, or any supplement ingredient.
Show all 11Show fewer
- Regular use of ergogenic supplements that cannot be discontinued before and during the study period.
- Smoking or regular use of nicotine products.
- Participation in another interventional study during the same period.
- Inability to comply with supplementation, monitoring, or testing procedures.
- Failure to provide written informed consent.
Trial locations and contacts
3 sites in 1 country.
Poland3 sites
Professional Football Training Center
Krakow
Professional Football Training Center
Lodz, 01-043
Professional Football Training Center
Warsaw, 01-043
About this study
Official title: Multidimensional Responses to Taurine-Caffeine Supplementation With and Without Phosphatidylserine in Professional Football Players: A 28-Day Randomised, Placebo- and Active-Controlled Trial
This 28-day randomised, placebo- and active-controlled trial investigated multidimensional responses to taurine-caffeine supplementation with or without phosphatidylserine in 65 male professional and highly trained football players.
Participants were allocated to placebo (PLA), taurine 1500 mg/day plus caffeine 200 mg/day (TC), or the same combination supplemented with phosphatidylserine 600 mg/day (TCP-600). Assessments were conducted before and after the intervention and covered physical performance, cognitive function, cardiac autonomic modulation and football-specific perceptual-cognitive performance.
The primary outcome was the proportion of participants showing favourable responses in at least two of four predefined assessment domains. The principal treatment comparison was TCP-600 versus TC, with comparisons involving placebo providing additional information on the effects of supplementation.
Read the detailed description
This randomised, masked, placebo- and active-controlled trial examined physical, cognitive, autonomic and football-specific perceptual-cognitive responses to 28 days of supplementation in professional and highly trained male football players.
Participants were randomly allocated to placebo (PLA), taurine 1500 mg/day plus caffeine 200 mg/day (TC), or taurine 1500 mg/day plus caffeine 200 mg/day and phosphatidylserine 600 mg/day (TCP-600). Assessments were performed before supplementation and after the intervention.
The primary outcome was the proportion of multidimensional responders, defined as participants meeting favourable-response criteria in at least two of four assessment domains: physical performance, cognitive performance, autonomic/recovery-related response and football-specific perceptual-cognitive performance.
Secondary assessments included 30 m sprint performance, cognitive reaction time, cardiac autonomic modulation assessed using LnRMSSD, readiness to train, perceived fatigue, football-specific decision-making, response time and visual search behaviour. The study also monitored supplementation adherence and adverse events.
The principal treatment comparison was TCP-600 versus TC, allowing assessment of the additional effect of phosphatidylserine within a fixed taurine-caffeine supplementation regimen. Comparisons with placebo were also conducted.
Post-completion clarification (November 2026): The original registration included external validation of a previously developed responder prediction model, with AUROC as a secondary outcome. This analysis was not performed because a previously finalised prediction model suitable for independent validation was unavailable. The analysis therefore focuses on observed multidimensional response and treatment-group comparisons. The omission of the originally registered prediction-model validation analysis is disclosed as a deviation from the initial analysis plan.
- Conditions
- Athletic Performance, Cognitive Fatigue, Exercise Recovery, Football-Specific Performance, Perceptual-cognitive Performance
- Being tested
- Placebo, Taurine, Caffeine, Phosphatidylserine
- Keywords
- Phosphatidylserine, Taurine, Caffeine, Football players, Soccer, Responder analysis, Heart rate variability, LnRMSSD, Reaction time, Mental fatigue, Sports nutrition, Individual responsiveness, Decision-making, Perceptual-cognitive performance, Recovery
- Medical subject headings
- Mental Fatigue
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PlaceboOther
Matching placebo capsules administered orally once daily for 28 consecutive days. The placebo was matched to the active supplements in appearance, number, packaging, and administration schedule.
TaurineDietary supplement
Taurine 1500 mg/day administered orally once daily in capsules for 28 consecutive days.
CaffeineDietary supplement
Anhydrous caffeine 200 mg/day administered orally once daily in capsules for 28 consecutive days.
PhosphatidylserineDietary supplement
Phosphatidylserine 600 mg/day administered orally once daily in capsules for 28 consecutive days.
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Participants assigned to this arm will receive placebo capsules for 28 consecutive days. Placebo capsules will be matched to the active supplement in appearance, number, packaging, and administration schedule. Receives: Other: Placebo |
| Taurine + Caffeine | Active comparator | Participants assigned to this arm will receive taurine 1500 mg/day and anhydrous caffeine 200 mg/day, administered orally once daily for 28 consecutive days. Matching placebo capsules will be used to maintain the same total number and appearance of capsules across study arms. Receives: Dietary Supplement: Taurine; Dietary Supplement: Caffeine |
| Taurine + Caffeine + Phosphatidylserine | Experimental | Participants assigned to this arm will receive a multi-ingredient supplementation protocol containing taurine 1500 mg/day, anhydrous caffeine 200 mg/day, and phosphatidylserine 600 mg/day, administered orally once daily for 28 consecutive days. This intervention is referred to as the TCP-600 protocol. Receives: Dietary Supplement: Taurine; Dietary Supplement: Caffeine; Dietary Supplement: Phosphatidylserine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of Participants Classified as Multidimensional Responders After 28 Days
Proportion of participants classified as multidimensional responders after 28 days of supplementation. A multidimensional responder will be defined as a participant meeting the predefined response criterion in at least two of four domains: physical performance/fatigue resistance, cognitive fatigue-related performance, recovery/readiness, and football-specific perceptual-cognitive performance. The outcome will be reported as the percentage of participants classified as multidimensional responders in each group.
Unit of Measure: percentage of participants
Measured: Baseline to post-intervention after 28 days of supplementation
Secondary outcomes (11)
Change in 30 m Sprint Time
Change in 30 m sprint performance from baseline to post-intervention testing. Sprint time will be measured using electronic timing gates. Participants will perform three maximal 30 m sprint trials separated by standardized recovery periods, and the best valid trial will be used for analysis.
Measured: Baseline to post-intervention after 28 days of supplementation
Change in Cognitive Fatigue Task Reaction Time
Change in reaction time during the computerized cognitive fatigue task from baseline to post-intervention testing after 28 days of supplementation. Reaction time will be measured during the predefined cognitive task performed under cognitive load. The outcome will be reported as the mean change in reaction time from baseline to post-intervention testing. Lower values indicate faster cognitive responses.
Unit of Measure: milliseconds
Measured: Baseline to post-intervention after 28 days of supplementation
Change in Perceived Mental Fatigue VAS Score
Change in perceived mental fatigue from baseline to post-intervention testing after 28 days of supplementation. Perceived mental fatigue will be assessed using a 0-10 visual analogue scale, where 0 indicates no perceived mental fatigue and 10 indicates maximal perceived mental fatigue. The outcome will be reported as the mean change in score from baseline to post-intervention testing. Higher scores indicate greater perceived mental fatigue.
Unit of Measure:
points on a 0-10 scale
Measured: Baseline to post-intervention after 28 days of supplementation.
Change in Final 3-Day Mean LnRMSSD
Change in heart rate variability from baseline monitoring to the final 3 days of supplementation. Heart rate variability will be expressed as the natural logarithm of the root mean square of successive RR interval differences. Morning HRV will be recorded under standardized resting conditions. The outcome will be reported as the mean change in final 3-day mean LnRMSSD compared with the baseline monitoring period.
Unit of Measure: ln(ms)
Measured: Baseline monitoring period to final 3 days of supplementation.
Change in Readiness-to-Train Rating Scale Score
Change in self-reported readiness to train from baseline monitoring to the final 3 days of supplementation. Readiness to train will be assessed using a single-item readiness-to-train rating scale scored from 1 to 10, where 1 indicates very poor readiness and 10 indicates excellent readiness. The outcome will be reported as the mean change in readiness-to-train score from the baseline monitoring period to the final 3-day supplementation period. Higher scores indicate greater perceived readiness to train.
Unit of Measure: points on a 1-10 scale
Measured: Baseline monitoring period to final 3 days of supplementation.
Change in Hooper and Mackinnon Wellness Questionnaire Fatigue Item Score
Change in self-reported fatigue from baseline monitoring to the final 3 days of supplementation. Fatigue will be assessed using the fatigue item of the Hooper and Mackinnon wellness questionnaire. The item is scored on a 1-7 scale. The outcome will be reported as the mean change in fatigue item score from the baseline monitoring period to the final 3-day supplementation period. Higher scores indicate greater perceived fatigue.
Unit of Measure: points on a 1-7 scale
Measured: Baseline monitoring period to final 3 days of supplementation.
Area Under the Receiver Operating Characteristic Curve for the Predefined Responder Model
Predictive performance of the predefined responder model in the independent validation cohort will be assessed using the area under the receiver operating characteristic curve. The model will compare predicted responder status with observed multidimensional responder status after 28 days of supplementation. Higher values indicate better discrimination.
Unit of Measure: area under the curve Post-completion clarification (November 2026): The originally planned AUROC analysis was not performed because a previously finalised prediction model was not available for independent validation. No prediction model was developed using the present cohort as a substitute. This deviation from the original analysis plan will be disclosed in the study publication.
Measured: Post-intervention after 28 days of supplementation.
Number of Participants With Supplement-Related Adverse Events
Number of participants reporting at least one supplement-related adverse event during the 28-day supplementation period. Participants will be asked to report gastrointestinal symptoms, sleep disturbances, headache, palpitations, nervousness, or any other unusual symptoms.
Unit of Measure: participants
Measured: During the 28-day supplementation period
Change in Football-Specific Video Decision-Making Task Response Time
Change in response time during the football-specific video decision-making task from baseline to post-intervention testing after 28 days of supplementation. Response time will be measured as the time from presentation of the decision prompt to participant response. The outcome will be reported as the mean change in response time from baseline to post-intervention testing. Lower values indicate faster football-specific decision-making.
Unit of Measure: milliseconds
Measured: Baseline to post-intervention after 28 days of supplementation.
Change in Football-Specific Video Decision-Making Task Accuracy
Change in football-specific decision-making accuracy from baseline to post-intervention testing after 28 days of supplementation. Decision-making accuracy will be assessed using a football-specific video decision-making task. Participants will view standardized football-specific scenarios and select the most appropriate tactical decision. The outcome will be reported as the mean change in the percentage of correct decisions from baseline to post-intervention testing. Higher values indicate better football-specific decision-making accuracy.
Unit of Measure: percentage of correct decisions
Measured: Baseline to post-intervention after 28 days of supplementation.
Change in Eye-Tracking Time to First Fixation on the Optimal Tactical Option
Change in visual search behavior from baseline to post-intervention testing after 28 days of supplementation. Visual search behavior will be assessed using eye-tracking during the football-specific video decision-making task. Time to first fixation will be defined as the time from scenario onset to the first fixation on the predefined optimal tactical option. The outcome will be reported as the mean change in time to first fixation from baseline to post-intervention testing. Lower values indicate faster visual orientation toward the optimal tactical option.
Unit of Measure: milliseconds
Measured: Baseline to post-intervention after 28 days of supplementation.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jul 2026
- Study start7 Sep 2026
- Primary completion8 Oct 2026
- Study completion8 Oct 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Athletic PerformanceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomly assigned in a 1:1:1 ratio to placebo, taurine plus caffeine, or taurine plus caffeine plus phosphatidylserine 600 mg/day for 28 days. The study will use a randomized, double-blind, placebo- and active-controlled, parallel-group design. This validation cohort will be used to test and extend predefined multidimensional responder profiles in professional football players, with particular focus on identifying players most likely to benefit from the addition of phosphatidylserine to taurine-caffeine supplementation.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 65 participants (actual)
Sponsor and investigators
- Lead sponsor
- Vizja University in Warsaw
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Krzysztof Mizera, Vizja University in Warsaw
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07710547
- Sponsor's protocol ID
- VIZJA-TCP600-RESP-2026 (28)
- Acronym
- TCP600-RESP
- Status last verified
- Nov 2026
- First submitted
- 4 Jul 2026
- Last updated
- 4 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be publicly shared due to participant confidentiality and the small, potentially identifiable nature of the professional athlete sample. Aggregated results may be reported in publications. Selected anonymized analysis outputs may be made available from the corresponding author upon reasonable request, where ethically and legally appropriate.
Study at a glance
From the registry record, last updated by the sponsor on 4 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multidimensional Responses to Taurine-Caffeine Supplementation With and Without Phosphatidylserine in Professional Football Players: A 28-Day Randomised, Placebo- and Active-Controlled Trial
- ClinicalTrials.gov ID
- NCT07710547
- Acronym / sponsor ID
- TCP600-RESP / VIZJA-TCP600-RESP-2026 (28)
- Conditions
- Athletic Performance, Cognitive Fatigue, Exercise Recovery, Football-Specific Performance, Perceptual-cognitive Performance
- Keywords
- Phosphatidylserine, Taurine, Caffeine, Football players, Soccer, Responder analysis, Heart rate variability, LnRMSSD
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 65 participants (actual)
- Lead sponsor
- Vizja University in WarsawUniversity, hospital or other
- Study start
- 7 Sep 2026 (actual)
- Primary completion
- 8 Oct 2026 (actual)
- Study completion
- 8 Oct 2026 (actual)
- First posted
- 17 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This 28-day randomised, placebo- and active-controlled trial investigated multidimensional responses to taurine-caffeine supplementation with or without phosphatidylserine in 65 male professional and highly trained football players.
Participants were allocated to placebo (PLA), taurine 1500 mg/day plus caffeine 200 mg/day (TC), or the same combination supplemented with phosphatidylserine 600 mg/day (TCP-600). Assessments were conducted before and after the intervention and covered physical performance, cognitive function, cardiac autonomic modulation and football-specific perceptual-cognitive performance.
The primary outcome was the proportion of participants showing favourable responses in at least two of four predefined assessment domains. The principal treatment comparison was TCP-600 versus TC, with comparisons involving placebo providing additional information on the effects of supplementation.
Detailed description
This randomised, masked, placebo- and active-controlled trial examined physical, cognitive, autonomic and football-specific perceptual-cognitive responses to 28 days of supplementation in professional and highly trained male football players.
Participants were randomly allocated to placebo (PLA), taurine 1500 mg/day plus caffeine 200 mg/day (TC), or taurine 1500 mg/day plus caffeine 200 mg/day and phosphatidylserine 600 mg/day (TCP-600). Assessments were performed before supplementation and after the intervention.
The primary outcome was the proportion of multidimensional responders, defined as participants meeting favourable-response criteria in at least two of four assessment domains: physical performance, cognitive performance, autonomic/recovery-related response and football-specific perceptual-cognitive performance.
Secondary assessments included 30 m sprint performance, cognitive reaction time, cardiac autonomic modulation assessed using LnRMSSD, readiness to train, perceived fatigue, football-specific decision-making, response time and visual search behaviour. The study also monitored supplementation adherence and adverse events.
The principal treatment comparison was TCP-600 versus TC, allowing assessment of the additional effect of phosphatidylserine within a fixed taurine-caffeine supplementation regimen. Comparisons with placebo were also conducted.
Post-completion clarification (November 2026): The original registration included external validation of a previously developed responder prediction model, with AUROC as a secondary outcome. This analysis was not performed because a previously finalised prediction model suitable for independent validation was unavailable. The analysis therefore focuses on observed multidimensional response and treatment-group comparisons. The omission of the originally registered prediction-model validation analysis is disclosed as a deviation from the initial analysis plan.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
- Model description
- Participants will be randomly assigned in a 1:1:1 ratio to placebo, taurine plus caffeine, or taurine plus caffeine plus phosphatidylserine 600 mg/day for 28 days. The study will use a randomized, double-blind, placebo- and active-controlled, parallel-group design. This validation cohort will be used to test and extend predefined multidimensional responder profiles in professional football players, with particular focus on identifying players most likely to benefit from the addition of phosphatidylserine to taurine-caffeine supplementation.
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Other: PlaceboParticipants assigned to this arm will receive placebo capsules for 28 consecutive days. Placebo capsules will be matched to the active supplement in appearance, number, packaging, and administration schedule. |
| Taurine + Caffeine | Active comparator | Dietary Supplement: Taurine, Dietary Supplement: CaffeineParticipants assigned to this arm will receive taurine 1500 mg/day and anhydrous caffeine 200 mg/day, administered orally once daily for 28 consecutive days. Matching placebo capsules will be used to maintain the same total number and appearance of capsules across study arms. |
| Taurine + Caffeine + Phosphatidylserine | Experimental | Dietary Supplement: Taurine, Dietary Supplement: Caffeine, Dietary Supplement: PhosphatidylserineParticipants assigned to this arm will receive a multi-ingredient supplementation protocol containing taurine 1500 mg/day, anhydrous caffeine 200 mg/day, and phosphatidylserine 600 mg/day, administered orally once daily for 28 consecutive days. This intervention is referred to as the TCP-600 protocol. |
Who may qualify
- Ages
- 18 to 37 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (10 listed)
- Male professional or highly trained football players aged 18-37 years.
- Regular participation in structured football training and team activities.
- Minimum of 5 years of structured football training experience.
- Regular involvement in club training during the study period.
- Medical clearance or no known contraindications to high-intensity exercise testing.
Key exclusion criteria (11 listed)
- Current musculoskeletal injury or illness preventing full participation in training or testing.
- Musculoskeletal injury within the previous 3 months that may affect sprint, football-specific performance, or perceptual-cognitive testing.
- Cardiovascular, metabolic, neurological, psychiatric, or other chronic disease that may affect safety or study outcomes.
- Diagnosed sleep disorder.
- Use of medication affecting heart rate, autonomic nervous system function, sleep, cognition, or exercise performance.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PlaceboMatching placebo capsules administered orally once daily for 28 consecutive days. The placebo was matched to the active supplements in appearance, number, packaging, and administration schedule. | Other | Placebo |
| TaurineTaurine 1500 mg/day administered orally once daily in capsules for 28 consecutive days. | Dietary supplement | Taurine + Caffeine, Taurine + Caffeine + Phosphatidylserine |
| CaffeineAnhydrous caffeine 200 mg/day administered orally once daily in capsules for 28 consecutive days. | Dietary supplement | Taurine + Caffeine, Taurine + Caffeine + Phosphatidylserine |
| PhosphatidylserinePhosphatidylserine 600 mg/day administered orally once daily in capsules for 28 consecutive days. | Dietary supplement | Taurine + Caffeine + Phosphatidylserine |
Primary outcome
Proportion of Participants Classified as Multidimensional Responders After 28 Days
Time frame: Baseline to post-intervention after 28 days of supplementation
Proportion of participants classified as multidimensional responders after 28 days of supplementation. A multidimensional responder will be defined as a participant meeting the predefined response criterion in at least two of four domains: physical performance/fatigue resistance, cognitive fatigue-related performance, recovery/readiness, and football-specific perceptual-cognitive performance. The outcome will be reported as the percentage of participants classified as multidimensional responders in each group. Unit of Measure: percentage of participants
11 secondary outcomes
Change in 30 m Sprint Time
Time frame: Baseline to post-intervention after 28 days of supplementation
Change in Cognitive Fatigue Task Reaction Time
Time frame: Baseline to post-intervention after 28 days of supplementation
Change in Perceived Mental Fatigue VAS Score
Time frame: Baseline to post-intervention after 28 days of supplementation.
Change in Final 3-Day Mean LnRMSSD
Time frame: Baseline monitoring period to final 3 days of supplementation.
Change in Readiness-to-Train Rating Scale Score
Time frame: Baseline monitoring period to final 3 days of supplementation.
Change in Hooper and Mackinnon Wellness Questionnaire Fatigue Item Score
Time frame: Baseline monitoring period to final 3 days of supplementation.
Area Under the Receiver Operating Characteristic Curve for the Predefined Responder Model
Time frame: Post-intervention after 28 days of supplementation.
Number of Participants With Supplement-Related Adverse Events
Time frame: During the 28-day supplementation period
Change in Football-Specific Video Decision-Making Task Response Time
Time frame: Baseline to post-intervention after 28 days of supplementation.
Change in Football-Specific Video Decision-Making Task Accuracy
Time frame: Baseline to post-intervention after 28 days of supplementation.
Change in Eye-Tracking Time to First Fixation on the Optimal Tactical Option
Time frame: Baseline to post-intervention after 28 days of supplementation.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Nov 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be publicly shared due to participant confidentiality and the small, potentially identifiable nature of the professional athlete sample. Aggregated results may be reported in publications. Selected anonymized analysis outputs may be made available from the corresponding author upon reasonable request, where ethically and legally appropriate.
Related trials for Athletic Performance
Recruiting
Acute Effects of Post-Exercise Hyperoxia on Recovery in Cycling
Athletic Performance, Hyperbaric Oxygenation
Not yet recruiting
Core Strength Training, Anthropometry, and Postural Control in Youth Optimist Sailors
Postural Control, Athletic Performance
Recruiting
Effects of Scapular Training on Adolescent Boxers
Sports Physical Therapy
Active, not recruiting
Effects of Blood Flow Restriction Training on Physical Function, Muscle Adaptations, and Performance in Roller Skaters
Athletic Performance Enhancement
Recruiting
UCLA Magnesium Formulation Athlete Study
Athletic Performance, Recovery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Taurine, Caffeine and Phosphatidylserine in people with Athletic Performance and Cognitive Fatigue, run by Vizja University in Warsaw at 3 sites in Poland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of Participants Classified as Multidimensional Responders After 28 Days (time frame: Baseline to post-intervention after 28 days of supplementation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2026.